rs11857380 — LIPC

LIPC — The Hepatic Lipase Remodeling Gene

Hepatic lipase, encoded by the LIPC gene¹¹ LIPC gene
Lipase C, hepatic type — LIPC gene on chromosome 15q22 encodes the enzyme responsible for hydrolysing triglycerides and phospholipids in circulating lipoproteins on chromosome 15, is a lipolytic enzyme synthesized in hepatocytes and anchored to liver sinusoidal endothelial cells. It serves two linked roles: converting the larger, cholesterol-rich HDL2 particles into smaller HDL3 particles (a catabolic step in the reverse-cholesterol transport cycle) and facilitating selective cholesterol ester uptake from IDL and LDL remnants into the liver. Higher hepatic lipase activity lowers circulating HDL cholesterol; lower activity raises it.

The Mechanism

rs11857380 is an intronic variant located within LIPC intron 1, and it is in linkage disequilibrium²² linkage disequilibrium
Linkage disequilibrium — non-random co-inheritance of nearby alleles on the same chromosome; when two variants are in strong LD, one reliably tags the other across populations with the well-characterised LIPC locus HDL-associated signals, including the promoter variant rs10468017 (also known as the LIPC −250G>A-region haplotype tag) and the promoter variant rs1800588 (−514C>T). These promoter variants alter the binding of transcription factors — in particular sterol-regulatory and sex-hormone-responsive elements — to the LIPC promoter, reducing LIPC transcriptional output by approximately 30% in carriers of the HDL-raising haplotype. Lower LIPC mRNA → less hepatic lipase protein → reduced hydrolysis of HDL2 phospholipids → accumulation of larger, more cholesterol-rich HDL2 particles and elevated plasma HDL cholesterol.

The G allele at rs11857380 tags this HDL-raising haplotype. Carriers of the G allele have, on average, 1.5–3.5 mg/dL higher HDL cholesterol per G allele, consistent with the effect sizes reported for the linked promoter variants across multiple populations.

The Evidence

A genome-wide association study of advanced AMD³³ genome-wide association study of advanced AMD
Neale et al. Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC). PNAS, 2010 identified the LIPC locus as protective for advanced age-related macular degeneration (AMD), with the functional promoter variant rs10468017 showing OR 0.82 per HDL-raising allele (P=1.34×10⁻⁸). The associated replication study⁴⁴ associated replication study
Neale et al. Associations of smoking, BMI, lutein, and LIPC rs10468017 with advanced AMD. IOVS, 2011 showed TT homozygotes at the LIPC locus had the strongest protection against advanced AMD (OR 0.70, P=1.8×10⁻³), with the effect appearing to be at least partly independent of circulating HDL levels, suggesting a direct retinal lipid metabolism role for hepatic lipase.

In terms of HDL genetics, the well-validated promoter variant rs1800588 (in strong LD with rs11857380 through the same haplotype block) raises HDL cholesterol by approximately 1.5 mg/dL per minor allele copy and 3.5 mg/dL in homozygous minor-allele carriers in European populations, confirmed in a systematic meta-analysis⁵⁵ systematic meta-analysis
Souverein et al. Genetic-epidemiological evidence on genes associated with HDL cholesterol. Eur J Cardiovasc Prev Rehab, 2003 of over 24,000 participants. The LIPC intron 1 haplotype study⁶⁶ LIPC intron 1 haplotype study
Hiura et al. Association of an intronic haplotype of LIPC with hyperalphalipoproteinemia. J Hum Genet, 2008 replicated significant associations between specific LIPC intronic haplotypes and hyperalphalipoproteinemia (elevated HDL >75th percentile) in two independent Japanese cohorts.

Sex-specific effects have been reported: the Guerra et al. study⁷⁷ Guerra et al. study
Guerra et al. LIPC variants in the promoter and intron 1 modify HDL-C levels in a sex-specific fashion. Atherosclerosis, 2009 found that in women, the minor allele of the linked LIPC intron 1 variant rs261342 was associated with an approximately 14% increase in HDL-C and a 30% reduced risk of low HDL, while associations in men were considerably weaker. This sex-hormone interaction — likely mediated by estrogen suppression of hepatic lipase transcription — means that premenopausal women may already have partially suppressed LIPC activity regardless of genotype.

The relationship between LIPC-elevated HDL and cardiovascular disease is not straightforward. While higher HDL generally correlates with lower CVD risk in observational studies, Mendelian randomization analyses have shown that genetically elevated HDL through the LIPC pathway does not uniformly translate to reduced coronary heart disease, likely because hepatic lipase activity also affects IDL remnant clearance and postprandial triglyceride metabolism — pathways with opposing cardiovascular effects.

Practical Actions

Carriers of the G allele at rs11857380 tend to have modestly elevated HDL cholesterol. For TG heterozygotes, the effect is approximately 1–2 mg/dL higher HDL on average. For GG homozygotes, the elevation may reach 3–4 mg/dL above average. This small but consistent benefit is worth confirming with a fasting lipid panel, which also captures triglycerides and LDL — both of which can independently signal metabolic risk even when HDL is elevated.

Carriers of two T alleles (TT) have average hepatic lipase activity and average HDL levels. Their HDL-C is more diet-responsive: dietary fat quality (polyunsaturated vs. saturated) influences HDL particle composition more noticeably in high-HL-activity individuals. Prioritizing omega-3-rich fish, olive oil, and avoiding trans fats can offset the absence of the genetic HDL-raising effect.

Interactions

The LIPC HDL-raising signal at rs11857380 interacts with CETP variants⁸⁸ CETP variants
CETP — cholesteryl ester transfer protein facilitates exchange of cholesterol esters from HDL to VLDL; strong LD with rs708272 (TaqIB) — individuals with both reduced CETP activity and reduced hepatic lipase activity accumulate the largest HDL2 particles. This combined effect has been studied in the context of HDL functional quality, since very large HDL particles (common in CETP + LIPC compound low-activity carriers) may paradoxically have reduced cholesterol efflux efficiency. See rs708272 (CETP TaqIB) for the complementary variant.

Hepatic lipase activity also modulates the efficiency of statin therapy on HDL: in individuals with lower baseline LIPC expression (G allele carriers), statin-induced HDL increases may be blunted because the HDL-raising pathway is already partially activated. Conversely, fibrate therapy (fenofibrate, gemfibrozil) raises HDL partly by reducing VLDL-derived triglyceride substrate for hepatic lipase, an effect that may be more prominent in TT carriers with normal-high HL activity.